The global pancreatic cancer treatment market size to be valued at USD 4.2 billion in 2025. The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel market growth. In addition, the growing geriatric population is expected to drive the growth of the pancreatic cancer treatment industry during the forecast period. Apart from lifestyle-dependent factors, a personal or family history of pancreatitis and BRCA2 mutation predisposes a person to pancreatic cancer.
A number of imaging techniques such as CT scan, MRI, and ultrasound are used for the diagnosis of the disease. Chemotherapy is the most common form of treatment provided by medical practitioners and oncologists. Currently, there are only four drugs approved by the U.S. FDA for the treatment of pancreatic cancer: ABRAXANE, (albumin-bound paclitaxel); Gemzar (gemcitabine); 5-FU (fluorouracil); and ONIVYDE (irinotecan liposome injection). Apart from these four drugs, FOLFIRINOX, a combination of three chemotherapy drugs (5-FU/leucovorin, irinotecan, and oxaliplatin) is commonly used in the treatment of metastatic pancreatic adenocarcinoma. Other emerging chemotherapies for advanced pancreatic cancer combined with agents already approved for use are being investigated in clinical trials.
In developing countries, governments are continuously investing a huge amount of funds in improving patient-centered care. The increasing geriatric population base, rising prevalence of pancreatic cancer cases, and rapid growth in foreign investments are expected to be witnessed over the forecast period in the developing nations of the Asia Pacific and the Middle East region.
Increasing investments in the healthcare sector, a steady rise in the geriatric population, and an increase in the number of cancer cases are projected to enhance market growth during the projection period. According to the International Diabetic Federation, in 2021, 537 million adults had diabetes and over 38.9% of adults worldwide were overweight. The risk of pancreatic cancer increases with rising incidences of diabetes and obesity, thus influencing the market. Furthermore, the rise in healthcare expenditure to aid infrastructure development, as well as initiatives undertaken by various government and private organizations, are projected to raise awareness about molecular biology, which in turn will propel market growth.
An increase in research & development activities will create new opportunities for the market. Furthermore, the growing frequency of drug launches and approvals benefits the market greatly. Growth and advancement in the development of new technologies and increased investments additionally provide beneficial opportunities for the market. For instance, the National cancer institute of the United States is currently researching the development of a blood test that could diagnose pancreatic cancer in its early stages. However, high costs related to the treatment and stringent government policies are restraints expected to slow down industry growth.
The global pancreatic cancer treatment industry has been segmented into the type of affected region and application. The affected region segment is categorized into exocrine and endocrine. Most of the pancreatic cancers diagnosed in the world belong to an exocrine category, thus the segment currently dominates the market. The endocrine type of cancer, although less prevalent, is still awaiting effective treatment modalities.
The investment in R&D is significant in both types of cancers. However, the increasing prevalence and growing reach of novel techniques in the developing regions are the factors expected to drive the growth of the exocrine segment throughout the forecast period.
Based on type, the pancreatic cancer market is segmented into chemotherapy, targeted therapy, and others that mainly include surgery, radiation techniques, and other therapies. Targeted therapy dominated the market in 2015 and is expected to dominate throughout the forecast period.
The factors driving growth include the introduction of the novel biologic therapies and targeted drugs in order to minimize the adverse effects of the existing therapies, including chemotherapy. Demand for targeted drugs is expected to rise significantly during the forecast period.
North America dominated the pancreatic cancer treatment industry with the largest revenue share in 2015. The dominance of this region is mainly attributed to the improved healthcare infrastructure, high adoption of pancreatic treatment procedures, and the presence of a large target population. In addition, an increasing incidence of pancreatic cancer is aggressively propelling the demand for treatment options.
On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period. The presence of well-established hospitals and critical care centers as well as a large population suffering from pancreatic cancer would boost the growth of the market in the Asia Pacific region. Furthermore, with the growing number of pancreatic cancer cases in the Asia Pacific region, the diagnosis and treatment of pancreatic cancer in the region must adhere to the same regimen as followed in western countries.
Currently, the global pancreatic cancer treatment industry is consolidated in nature with only a few top companies capturing the major share of the market. Some of the top companies operating in this market are Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.
Numerous companies are focusing on the introduction of technologically advanced products in order to gain a foothold in the fast-developing medical devices sector. In addition, partnerships, collaborations, and mergers with well-established players are the major strategies deployed by top players to increase the market share during the forecast period.
In January 2022, for pancreatic cancer treatment, the U.S. Food and Drug Administration (FDA) gave orphan drug status to multitargeted T-cell therapy. This therapy has shown the potential to elicit sustained responses in individuals with advanced or metastatic pancreatic cancer when combined with chemotherapy as a first-line therapeutic option
In February 2022, Eli Lilly and Company and UNICEF declared a collaboration aimed at improving healthcare facilities for around 10 million children and adolescents suffering from non-communicable diseases
In July 2021, Novartis’ NIS793 monoclonal antibody received the Orphan Drug Designation (ODD) from the FDA, with regard to pancreatic cancer
Report Attribute |
Details |
Revenue forecast in 2025 |
USD 4.2 billion |
Base year for estimation |
2015 |
Forecast period |
2016 - 2025 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2016 to 2025 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Affected region, treatment, and region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; China; Japan; Brazil; Mexico; South Africa |
Key companies profiled |
Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Pfizer, Inc. |
Customization scope |
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, & country levels as well as provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the Pancreatic Cancer Treatment Market on the basis of affected region, type, and region:
Affected region Outlook (Revenue, USD Million, 2014 - 2025)
Exocrine
Endocrine
Type Outlook (Revenue, USD Million, 2014 - 2025)
Chemotherapy
Targeted Therapy
Others
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
UK
Germany
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
MEA
South Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.